National Pediculosis Association Marks 25 Years of Advocating Important Message: ‘It’s Not About Lice, It’s About Kids’
 Furl It |
This September, the All Out Comb Out has special significance. That’s because the National Pediculosis Association is celebrating its silver anniversary. For the past 25 years, the association has kept kids happy and lice free through basic measures of routine screening, early detection and thorough removal of all the lice and nits.
(PRWEB) September 3, 2008 — A lot can change in 25 years, but the National Pediculosis Association’s commitment to protecting children from the misuse and abuse of pesticides has never wavered. Each year NPA’s signature outreach, the All Out Comb Out, coincides with its sponsorship of National Head Lice Prevention Month and the back to school season. The National Pediculosis Association’s message is timeless, as relevant now as it was 25 years ago.
“Our silver anniversary is a great time to look back and celebrate what we’ve achieved,” said Deborah Altschuler of the NPA. “Thanks to our awareness message of early detection and regular checks, we’ve kept countless kids free from lice and nits and the anxiety that often comes with them.”
The National Pediculosis Association has even developed a sing-song mantra to mark the All Out Comb Out: screen, detect, remove, protect.
“Combing to find and remove head lice and their nits as early as possible is the best and safest approach we know,” Altschuler said. “Combing for lice and nits follows the precautionary principle. It’s just good basic hygiene for kids.”
So this month, in celebration of the National Pediculosis Association’s 25th anniversary, break out the LiceMeister comb and screen your child for head lice and their nits.
For more information about the National Pediculosis Association, please visit http://headlice.org.
Media Contact:
Deborah Altschuler
617-905-0176
npa (at) headlice.org
See Also:
- Explosion Proof Paint Spray Booth Lights Round Out OSHA Compliant Lights for Magnalight.com
- Digital Media & Touch Screen Technology: An Increasing Trend In Education - WGBH Teachers’ Domain Expands Free Classroom Resources For Teachers
- Raxco Software’s PerfectDisk 2008 Disk Defragmenter Available for Hyper-V
- Case Study: Clark Construction Expedites Nationals Park Punchlist with LATISTA, Finishing New Ballpark in Record Time
- Uecomm Ethernet Technology Delivers Scalability & Resilience
National Pediculosis Association Marks 25 Years of Advocating Important Message: ‘It’s Not About Lice, It’s About Kids’
| Furl It |
This September, the All Out Comb Out has special significance. That’s because the National Pediculosis Association is celebrating its silver anniversary. For the past 25 years, the association has kept kids happy and lice free through basic measures of routine screening, early detection and thorough removal of all the lice and nits.
(PRWEB) September 3, 2008 — A lot can change in 25 years, but the National Pediculosis Association’s commitment to protecting children from the misuse and abuse of pesticides has never wavered. Each year NPA’s signature outreach, the All Out Comb Out, coincides with its sponsorship of National Head Lice Prevention Month and the back to school season. The National Pediculosis Association’s message is timeless, as relevant now as it was 25 years ago.
“Our silver anniversary is a great time to look back and celebrate what we’ve achieved,” said Deborah Altschuler of the NPA. “Thanks to our awareness message of early detection and regular checks, we’ve kept countless kids free from lice and nits and the anxiety that often comes with them.”
The National Pediculosis Association has even developed a sing-song mantra to mark the All Out Comb Out: screen, detect, remove, protect.
“Combing to find and remove head lice and their nits as early as possible is the best and safest approach we know,” Altschuler said. “Combing for lice and nits follows the precautionary principle. It’s just good basic hygiene for kids.”
So this month, in celebration of the National Pediculosis Association’s 25th anniversary, break out the LiceMeister comb and screen your child for head lice and their nits.
For more information about the National Pediculosis Association, please visit http://headlice.org.
Media Contact:
Deborah Altschuler
617-905-0176
npa (at) headlice.org
See Also:
- Instantiations Updates GWT Designer with Support for Google Web Toolkit 1.5 Release;
- Twelve Ways to Use Your Intranet to Cut Costs
- ColumbiaSoft Releases Document Locator v5.2 And Sets The Stage For New Email Compliance Options
- The 1st Annual Great American Small Business Challenge Encourages Small Businesses to Achieve Big Results
- Dr. Shan Nair of Nair & Co. Wins the Gullands Excellence Award : Presented by the NRI Institute at Their London Awards Gala
Anadis Commercializing “BioGard” Adjunctive Therapy for HIV & AIDS
| Furl It |
MELBOURNE, Australia (Business Wire EON/PRWEB ) September 4, 2008 — Anadis (ASX: ANX; OTC: ANDIY) announced today its commercialization of a new product, BioGard™, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS. The product is intended to enhance current treatment regimens and improve the efficacy of immune system repair during highly active antiretroviral treatment (HAART) treatment. The gastrointestinal immune system is increasingly recognized as having an important role in the progression of HIV-related immune depletion and local gastro-intestinal symptoms have been a great concern to HIV/AIDS patients. The target market for the product includes over 1 million patients in the U.S., 2 million in Europe and Central Asia and more than 30 million worldwide. BioGard is intended to be marketed as a medical food, used under medical supervision, although available for purchase over-the-counter, and is expected to be launched in 2009 following results from a phase IIIb/IV multi-site clinical trial beginning this year that is an advanced stage of planning.
The product’s active ingredient is a proprietary oral formulation of antigen-targeted Bovine Colostrum Powder (BCP) that has been approved by Australia’s regulatory agency, the Therapeutic Goods Administration (TGA). The product will be first available in tablet format manufactured and packed in a TGA registered GMP tableting facility. Like other Anadis BCP products, the freeze-dried active ingredients in BioGard tablets is obtained from commercial dairy cow herds utilizing the patented Anadis hyper-immunization technology and deploying unique collection processes to assure quality . The BSE free cows in these herds, as well as being vaccinated for routine cattle pathogens, have been vaccinated with a proprietary Anadis vaccine containing important lipopolysaccarides found in gram negative bacterial cell walls that are implicated as key drivers of AIDS pathogenesis. Data supporting this work was first presented recently by scientists from Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria and the Department of Microbiology & Immunology, University of Melbourne at the Australian Society for Microbiology annual meeting held in Melbourne.
Anadis is now in advanced discussion with a major AIDS-research institution to test the efficacy of BioGard in a multi-site, randomized double-blind, placebo controlled study. The goal of the study is to measure the effect of combination antiretroviral therapy intensification with BioGard on CD4+ outcomes in HIV-1 infected individuals with suboptimal CD4 response to therapy despite prolonged virologic suppression.
Details of the study will be released at a later time.
Dr. Zeil Rosenberg, CEO of Anadis stated: “Combination anti-retroviral therapy (cART) intensification and use of our new antigen-targeted bovine colostrum added to stable cART may help restore immunological integrity of the intestinal mucosal barrier thereby controlling microbial translocation, diminishing immune activation and resulting in better CD4+ cell reconstitution. This is expected to significantly improve the efficacy and safety profile of drugs in the HIV area.”
Dr. Oren Fuerst, VP Business Development of Anadis, stated: “BioGard was developed based on a novel approach related to the inflammation process and is another manifestation of the versatility of our platform. We continue to develop and rapidly commercialize products that are both important to large populations and which have a clear commercial market. In this case, our products may increase the efficacy and safety of drugs with current revenue in excess of $5bn per year.”
Anadis Limited (ASX: ANX; OTC: ANDIY) is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Anadis’ proprietary technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases. The all-natural colostrum-derived platform, its high safety profile when administered orally and the proprietary methods of manufacturing, allows for short time-frame from bench to market with high manufacturing scalability.
See Also:
- Dr. Shan Nair of Nair & Co. Wins the Gullands Excellence Award : Presented by the NRI Institute at Their London Awards Gala
- Explosion Proof Paint Spray Booth Lights Round Out OSHA Compliant Lights for Magnalight.com
- The 1st Annual Great American Small Business Challenge Encourages Small Businesses to Achieve Big Results
- Blackbaud’s NetWits Live to Focus on Social Media and Interactive Marketing Strategies for Nonprofits
- Dr. Deborah Stokes Presents Findings on Study Involving Use of Neurofeedback Video Games to Treat Migraine Headaches
Anadis Commercializing “BioGard” Adjunctive Therapy for HIV & AIDS
| Furl It |
MELBOURNE, Australia (Business Wire EON/PRWEB ) September 4, 2008 — Anadis (ASX: ANX; OTC: ANDIY) announced today its commercialization of a new product, BioGard™, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS. The product is intended to enhance current treatment regimens and improve the efficacy of immune system repair during highly active antiretroviral treatment (HAART) treatment. The gastrointestinal immune system is increasingly recognized as having an important role in the progression of HIV-related immune depletion and local gastro-intestinal symptoms have been a great concern to HIV/AIDS patients. The target market for the product includes over 1 million patients in the U.S., 2 million in Europe and Central Asia and more than 30 million worldwide. BioGard is intended to be marketed as a medical food, used under medical supervision, although available for purchase over-the-counter, and is expected to be launched in 2009 following results from a phase IIIb/IV multi-site clinical trial beginning this year that is an advanced stage of planning.
The product’s active ingredient is a proprietary oral formulation of antigen-targeted Bovine Colostrum Powder (BCP) that has been approved by Australia’s regulatory agency, the Therapeutic Goods Administration (TGA). The product will be first available in tablet format manufactured and packed in a TGA registered GMP tableting facility. Like other Anadis BCP products, the freeze-dried active ingredients in BioGard tablets is obtained from commercial dairy cow herds utilizing the patented Anadis hyper-immunization technology and deploying unique collection processes to assure quality . The BSE free cows in these herds, as well as being vaccinated for routine cattle pathogens, have been vaccinated with a proprietary Anadis vaccine containing important lipopolysaccarides found in gram negative bacterial cell walls that are implicated as key drivers of AIDS pathogenesis. Data supporting this work was first presented recently by scientists from Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria and the Department of Microbiology & Immunology, University of Melbourne at the Australian Society for Microbiology annual meeting held in Melbourne.
Anadis is now in advanced discussion with a major AIDS-research institution to test the efficacy of BioGard in a multi-site, randomized double-blind, placebo controlled study. The goal of the study is to measure the effect of combination antiretroviral therapy intensification with BioGard on CD4+ outcomes in HIV-1 infected individuals with suboptimal CD4 response to therapy despite prolonged virologic suppression.
Details of the study will be released at a later time.
Dr. Zeil Rosenberg, CEO of Anadis stated: “Combination anti-retroviral therapy (cART) intensification and use of our new antigen-targeted bovine colostrum added to stable cART may help restore immunological integrity of the intestinal mucosal barrier thereby controlling microbial translocation, diminishing immune activation and resulting in better CD4+ cell reconstitution. This is expected to significantly improve the efficacy and safety profile of drugs in the HIV area.”
Dr. Oren Fuerst, VP Business Development of Anadis, stated: “BioGard was developed based on a novel approach related to the inflammation process and is another manifestation of the versatility of our platform. We continue to develop and rapidly commercialize products that are both important to large populations and which have a clear commercial market. In this case, our products may increase the efficacy and safety of drugs with current revenue in excess of $5bn per year.”
Anadis Limited (ASX: ANX; OTC: ANDIY) is a biopharmaceutical company focused on antigen-primed, dairy-derived health products. Anadis’ proprietary technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases. The all-natural colostrum-derived platform, its high safety profile when administered orally and the proprietary methods of manufacturing, allows for short time-frame from bench to market with high manufacturing scalability.
See Also:
- LiveTime Releases Spanish Edition of its Web 2.0 Service Desk
- Instantiations Updates GWT Designer with Support for Google Web Toolkit 1.5 Release;
- Dr. Deborah Stokes Presents Findings on Study Involving Use of Neurofeedback Video Games to Treat Migraine Headaches
- Midbrook Helps Companies Meet ISO16232 Cleanliness Standards
- Case Study: Clark Construction Expedites Nationals Park Punchlist with LATISTA, Finishing New Ballpark in Record Time
Eisai’s Alex Scott Featured As Industry Leader At BioNetwork 2008 in Laguna Niguel, CA
| Furl It |
Alex Scott, Vice President, Business Development at Eisai Corporation of North America will present on October 6 at BioNetwork 2008 - “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity.”
New York, NY (PRWEB) September 4, 2008 — Alex Scott, Vice President, Business Development at Eisai Corporation of North America, oversees business development activities for all Eisai companies in the United States, specifically targeting opportunities in Eisai’s three areas of therapeutic focus - neurology, gastrointestinal disorders, and oncology/critical care. Mr. Scott joined Eisai in 1992 as Manager of Corporate Affairs at Eisai Corporation of North America. Before assuming his current role, he held several positions of increasing responsibility in Corporate Affairs, Planning and Business Development within Eisai U.S. operations. During this time, Mr. Scott helped craft Eisai’s U.S. globalization strategy and establish a commercial infrastructure, negotiating global alliances with Pfizer and PriCara®, a division of Ortho-McNeil-Janssen Pharmaceuticals for Aricept® (donepezil hydrochloride tablets) and Aciphex®/Pariet® (rabeprazole sodium) tablets, respectively. Both products, discovered and developed by Eisai, have realized billion-dollar status in the United States. Scott’s presentation on October 6, 2008, “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity” will establish how this industry leading company incorporated key elements of success in post-merger integrations.
Highlights of the keynote presentation will include:
- Assessing the strategic value of an M&A deal
- Addressing potential integration challenges
- Sharing best practices: looking at the successes of Eisai’s recent acquisitions of MGI PHARMA, INC. and Morphotek, Inc.
BioNetwork 2008 is the premier biotech and pharmaceutical business development partnering conference. The 3 day interactive forum tackles issues created by an extremely competitive partnering environment requiring strong relationship building, extensive partnership scouting and rapid decision making processes. To overcome these issues, BioNetwork provides a series of thought-provoking sessions combined with exclusive networking events to ensure maximized return on investment.
Event Details:
Partnering Made Easy: One-On-One Meeting Rooms, available throughout all 3 days of BioNetwork!
As an attendee, you have the opportunity to organize a meeting with a colleague or potential partner in the one-to-one meeting rooms. Book one of these closed door meeting rooms for up to 30 minutes at a time through our easy-to-use partnering website. This is your chance to move potential partners to the next stage, and to identify the mutual benefits of your potential alliance in a private setting. Book your room and begin launching successful partnerships right away.
October 6, 2008
Therapeutic Roundtables
Interested in meeting other companies partnering in your therapeutic area of interest? Join business development and licensing heads from companies in oncology, auto-immune disease, cardiovascular diseases, biopharmaceuticals and vaccines, drug delivery technologies and others, as they discuss where strategic partnerships can be build and what lays on the road ahead.
October 7, 2008
Therapeutic Focus Partnering Primers:
Enabling small biotechs to present their compounds/technologies available for partnering, these 10 minute presentations will provide innovative companies the opportunity to demonstrate their value in sessions focused on their therapeutic area of interest. Therapeutic areas to be presented include:
- Metabolic Diseases
- Central Nervous System
- Inflammatory Diseases
- Infectious Diseases
About Worldwide Business Research
WBR is the world’s biggest large-scale conference company and part of the PLS group, one of the world’s leading providers of strategic business intelligence with 16 offices worldwide.
Every year over 10,000 senior executives from Fortune 1000 companies attend over 60 annual conferences - a true ‘who’s who’ of today’s corporate world. From Automotive events in Bucharest to Logistics conferences in Arizona and Finance summits in Hong Kong, WBR is dedicated to exceeding the needs of its customers around the world.
For more information about Worldwide Business Research, please visit www.wbresearch.com.
For more information about BioNetwork 2008 and to register and receive a 25% discount with booking code 10386.003XV00PR, please visit www.bionetworkus.com
Contacts:
Speaking Opportunities
Priya Pandian
(646) 200-7536
priya.pandian@wbresearch.com
Sponsorship Opportunities
Phillip Denis
646-200-7537
phillip.denis@wbresearch.com
Media Partnerships
Gaianti Surajbali
212-885-2665
gsurajbali@wbresearch.com
Conference Services
Rachel Schwartz
(212) 885-2756
rschwartz@wbresearh.com
See Also:
- LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences
- Nature’s Bounty is Growing Greener
- The 1st Annual Great American Small Business Challenge Encourages Small Businesses to Achieve Big Results
- Instantiations Updates GWT Designer with Support for Google Web Toolkit 1.5 Release;
- Explosion Proof Paint Spray Booth Lights Round Out OSHA Compliant Lights for Magnalight.com
Eisai’s Alex Scott Featured As Industry Leader At BioNetwork 2008 in Laguna Niguel, CA
| Furl It |
Alex Scott, Vice President, Business Development at Eisai Corporation of North America will present on October 6 at BioNetwork 2008 - “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity.”
New York, NY (PRWEB) September 4, 2008 — Alex Scott, Vice President, Business Development at Eisai Corporation of North America, oversees business development activities for all Eisai companies in the United States, specifically targeting opportunities in Eisai’s three areas of therapeutic focus - neurology, gastrointestinal disorders, and oncology/critical care. Mr. Scott joined Eisai in 1992 as Manager of Corporate Affairs at Eisai Corporation of North America. Before assuming his current role, he held several positions of increasing responsibility in Corporate Affairs, Planning and Business Development within Eisai U.S. operations. During this time, Mr. Scott helped craft Eisai’s U.S. globalization strategy and establish a commercial infrastructure, negotiating global alliances with Pfizer and PriCara®, a division of Ortho-McNeil-Janssen Pharmaceuticals for Aricept® (donepezil hydrochloride tablets) and Aciphex®/Pariet® (rabeprazole sodium) tablets, respectively. Both products, discovered and developed by Eisai, have realized billion-dollar status in the United States. Scott’s presentation on October 6, 2008, “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity” will establish how this industry leading company incorporated key elements of success in post-merger integrations.
Highlights of the keynote presentation will include:
- Assessing the strategic value of an M&A deal
- Addressing potential integration challenges
- Sharing best practices: looking at the successes of Eisai’s recent acquisitions of MGI PHARMA, INC. and Morphotek, Inc.
BioNetwork 2008 is the premier biotech and pharmaceutical business development partnering conference. The 3 day interactive forum tackles issues created by an extremely competitive partnering environment requiring strong relationship building, extensive partnership scouting and rapid decision making processes. To overcome these issues, BioNetwork provides a series of thought-provoking sessions combined with exclusive networking events to ensure maximized return on investment.
Event Details:
Partnering Made Easy: One-On-One Meeting Rooms, available throughout all 3 days of BioNetwork!
As an attendee, you have the opportunity to organize a meeting with a colleague or potential partner in the one-to-one meeting rooms. Book one of these closed door meeting rooms for up to 30 minutes at a time through our easy-to-use partnering website. This is your chance to move potential partners to the next stage, and to identify the mutual benefits of your potential alliance in a private setting. Book your room and begin launching successful partnerships right away.
October 6, 2008
Therapeutic Roundtables
Interested in meeting other companies partnering in your therapeutic area of interest? Join business development and licensing heads from companies in oncology, auto-immune disease, cardiovascular diseases, biopharmaceuticals and vaccines, drug delivery technologies and others, as they discuss where strategic partnerships can be build and what lays on the road ahead.
October 7, 2008
Therapeutic Focus Partnering Primers:
Enabling small biotechs to present their compounds/technologies available for partnering, these 10 minute presentations will provide innovative companies the opportunity to demonstrate their value in sessions focused on their therapeutic area of interest. Therapeutic areas to be presented include:
- Metabolic Diseases
- Central Nervous System
- Inflammatory Diseases
- Infectious Diseases
About Worldwide Business Research
WBR is the world’s biggest large-scale conference company and part of the PLS group, one of the world’s leading providers of strategic business intelligence with 16 offices worldwide.
Every year over 10,000 senior executives from Fortune 1000 companies attend over 60 annual conferences - a true ‘who’s who’ of today’s corporate world. From Automotive events in Bucharest to Logistics conferences in Arizona and Finance summits in Hong Kong, WBR is dedicated to exceeding the needs of its customers around the world.
For more information about Worldwide Business Research, please visit www.wbresearch.com.
For more information about BioNetwork 2008 and to register and receive a 25% discount with booking code 10386.003XV00PR, please visit www.bionetworkus.com
Contacts:
Speaking Opportunities
Priya Pandian
(646) 200-7536
priya.pandian@wbresearch.com
Sponsorship Opportunities
Phillip Denis
646-200-7537
phillip.denis@wbresearch.com
Media Partnerships
Gaianti Surajbali
212-885-2665
gsurajbali@wbresearch.com
Conference Services
Rachel Schwartz
(212) 885-2756
rschwartz@wbresearh.com
See Also:
- Blackbaud’s NetWits Live to Focus on Social Media and Interactive Marketing Strategies for Nonprofits
- Digital Media & Touch Screen Technology: An Increasing Trend In Education - WGBH Teachers’ Domain Expands Free Classroom Resources For Teachers
- Twelve Ways to Use Your Intranet to Cut Costs
- LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences
- Dr. Deborah Stokes Presents Findings on Study Involving Use of Neurofeedback Video Games to Treat Migraine Headaches
Eisai’s Alex Scott Featured As Industry Leader At BioNetwork 2008 in Laguna Niguel, CA
| Furl It |
Alex Scott, Vice President, Business Development at Eisai Corporation of North America will present on October 6 at BioNetwork 2008 - “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity.”
New York, NY (PRWEB) September 4, 2008 — Alex Scott, Vice President, Business Development at Eisai Corporation of North America, oversees business development activities for all Eisai companies in the United States, specifically targeting opportunities in Eisai’s three areas of therapeutic focus - neurology, gastrointestinal disorders, and oncology/critical care. Mr. Scott joined Eisai in 1992 as Manager of Corporate Affairs at Eisai Corporation of North America. Before assuming his current role, he held several positions of increasing responsibility in Corporate Affairs, Planning and Business Development within Eisai U.S. operations. During this time, Mr. Scott helped craft Eisai’s U.S. globalization strategy and establish a commercial infrastructure, negotiating global alliances with Pfizer and PriCara®, a division of Ortho-McNeil-Janssen Pharmaceuticals for Aricept® (donepezil hydrochloride tablets) and Aciphex®/Pariet® (rabeprazole sodium) tablets, respectively. Both products, discovered and developed by Eisai, have realized billion-dollar status in the United States. Scott’s presentation on October 6, 2008, “Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity” will establish how this industry leading company incorporated key elements of success in post-merger integrations.
Highlights of the keynote presentation will include:
- Assessing the strategic value of an M&A deal
- Addressing potential integration challenges
- Sharing best practices: looking at the successes of Eisai’s recent acquisitions of MGI PHARMA, INC. and Morphotek, Inc.
BioNetwork 2008 is the premier biotech and pharmaceutical business development partnering conference. The 3 day interactive forum tackles issues created by an extremely competitive partnering environment requiring strong relationship building, extensive partnership scouting and rapid decision making processes. To overcome these issues, BioNetwork provides a series of thought-provoking sessions combined with exclusive networking events to ensure maximized return on investment.
Event Details:
Partnering Made Easy: One-On-One Meeting Rooms, available throughout all 3 days of BioNetwork!
As an attendee, you have the opportunity to organize a meeting with a colleague or potential partner in the one-to-one meeting rooms. Book one of these closed door meeting rooms for up to 30 minutes at a time through our easy-to-use partnering website. This is your chance to move potential partners to the next stage, and to identify the mutual benefits of your potential alliance in a private setting. Book your room and begin launching successful partnerships right away.
October 6, 2008
Therapeutic Roundtables
Interested in meeting other companies partnering in your therapeutic area of interest? Join business development and licensing heads from companies in oncology, auto-immune disease, cardiovascular diseases, biopharmaceuticals and vaccines, drug delivery technologies and others, as they discuss where strategic partnerships can be build and what lays on the road ahead.
October 7, 2008
Therapeutic Focus Partnering Primers:
Enabling small biotechs to present their compounds/technologies available for partnering, these 10 minute presentations will provide innovative companies the opportunity to demonstrate their value in sessions focused on their therapeutic area of interest. Therapeutic areas to be presented include:
- Metabolic Diseases
- Central Nervous System
- Inflammatory Diseases
- Infectious Diseases
About Worldwide Business Research
WBR is the world’s biggest large-scale conference company and part of the PLS group, one of the world’s leading providers of strategic business intelligence with 16 offices worldwide.
Every year over 10,000 senior executives from Fortune 1000 companies attend over 60 annual conferences - a true ‘who’s who’ of today’s corporate world. From Automotive events in Bucharest to Logistics conferences in Arizona and Finance summits in Hong Kong, WBR is dedicated to exceeding the needs of its customers around the world.
For more information about Worldwide Business Research, please visit www.wbresearch.com.
For more information about BioNetwork 2008 and to register and receive a 25% discount with booking code 10386.003XV00PR, please visit www.bionetworkus.com
Contacts:
Speaking Opportunities
Priya Pandian
(646) 200-7536
priya.pandian@wbresearch.com
Sponsorship Opportunities
Phillip Denis
646-200-7537
phillip.denis@wbresearch.com
Media Partnerships
Gaianti Surajbali
212-885-2665
gsurajbali@wbresearch.com
Conference Services
Rachel Schwartz
(212) 885-2756
rschwartz@wbresearh.com
See Also:
- Case Study: Clark Construction Expedites Nationals Park Punchlist with LATISTA, Finishing New Ballpark in Record Time
- IMAGINiT Technologies Offers Free Download of Revit Global Light Utility for 3ds Max
- Instantiations Updates GWT Designer with Support for Google Web Toolkit 1.5 Release;
- Raxco Software’s PerfectDisk 2008 Disk Defragmenter Available for Hyper-V
- LiveTime Releases Spanish Edition of its Web 2.0 Service Desk
Georgetown University to Offer MyCareTeam™ Diabetes Management Software to Employees & Family Members
| Furl It |
Georgetown University, in conjunction with MyCareTeam, Inc., has announced that MyCareTeam’s popular diabetes management software, MCT-Diabetes, is immediately available to all Georgetown University employees and family members through the university’s health and wellness program, GUWellness: Mind, Body, Soul.
Acton, MA (PRWEB) September 3, 2008 — Georgetown University, in conjunction with MyCareTeam, Inc., has announced that MyCareTeam’s popular diabetes management software, MCT-Diabetes, is immediately available to all Georgetown University employees and family members through the university’s health and wellness program, GUWellness: Mind, Body, Soul.
Georgetown employees can now use MCT-Diabetes to securely upload blood glucose (sugar) readings from their glucose meter and communicate electronically with their caregivers. MCT-Diabetes, developed in conjunction with Georgetown University Medical Center and recently cleared by the FDA, guides people with diabetes to make the required behavioral and medication changes supported by frequent feedback and input from caregivers.
“We are delighted to be the first university in the country to offer our community the opportunity to improve their diabetes health using the MCT-Diabetes software.” said Charles DeSantis, Associate Vice President and Chief Benefits Officer of Georgetown University. “This product is a great fit for GUWellness and connects with our mission of providing our faculty and staff with access to the best tools to improve their health and ultimately reduce overall health costs.”
MCT-Diabetes offers a unique and personalized way to share and monitor blood glucose levels, keep track of medications, log blood pressure, track lab results, and build and maintain an exercise log. The product also allows people with diabetes to invite individuals into their health-management support circle, and provides an interactive method for receiving feedback in the form of charts and graphs.
“MCT-Diabetes has been shown in clinical trials to reduce blood glucose and HbA1c levels.” said Jim Mingle, CEO of MyCareTeam, Inc. “The Georgetown roll-out of MCT-Diabetes is an innovative example of how health and wellness organizations can use behavior management tools like MCT-Diabetes to improve the overall health of their employees who have diabetes.”
MyCareTeam recently announced integration of MCT-Diabetes with Google Health. Google Health allows consumers to enter and maintain their own medical data and electronically send that information to systems, which are connected to Google Health. MyCareTeam’s diabetes management software, MCT-Diabetes, integrated with Google Health, will allow consumers to securely transfer diabetes related information to and from the Google Health medical data repository. The data can be transferred to any other medical applications that are also integrated with Google Health.
MCT-Diabetes is available to wellness programs, consumers and health professionals directly from MyCareTeam and select distribution channels. Monthly and yearly subscriptions are available. Visit www.mycareteam.com for more information.
About MyCareTeam, Inc.
MyCareTeam, Inc. was founded to provide software offerings that are designed to help people with diabetes to collaborate and manage their illness while reducing overall healthcare costs. The company’s diabetes offering, MCT-Diabetes is cleared by the FDA and has been successfully used for over five years by patients, doctors and nurses to dramatically improve the health and wellness in people with diabetes and reduce overall healthcare costs. MyCareTeam is headquartered in Acton, Massachusetts and the company’s website is www.mycareteam.com.
See Also:
- What Price Presidency?
- DuPont Building Innovations Announces Price Increases
- Men, Woman and Kids to Shave Heads Bald to Raise Money for Childhood Cancer Research at The Shillelagh Club in West Orange, N.J.
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- VisualCalc Announces New Public Dashboard Website Focused on Today’s Biggest Issues: www.PublicDashboards.com
[Via PRWeb: Medical Diabetes]
Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians
| Furl It |
A new survey by Medical Economics details surprising statistics on earnings and productivity for healthcare professionals in the United States, including an increase in wages for many doctors accompanied by a decrease in patient loads.
New York, NY (PRWEB) September 3, 2008 — A newly-released 2008 Medical Economics survey focusing on earnings and productivity for physicians in America features some intriguing statistics concerning the financial successes and challenges faced by today’s professional medical community. The March and April 2008 survey polled more than 175,000 American physicians on practice size, productivity, compensation, expenditures, third-party payer arrangements and basic demographics. Details of the survey are available by following the Medical Economics survey link.
“This survey points to some fascinating trends for primary care physicians in terms of geography, business models, wages and medical practice areas,” explains Sean Keating, Product Director for Modern Medicine, the website for doctors that offers medical industry news and an online medical library as a resource for physicians. “We polled more than 175,000 American physicians on many demographic areas, and the resulting statistics are very enlightening about the changing face of healthcare and physician lifestyles. I think every physician in the U.S. can benefit from this trenchant medical news.”
Among some of the findings discussed in the survey is the decrease in weekly patient visits nationwide for primary care physicians while patient loads for general and family practitioners increased, as well as the earnings discrepancy for physicians based upon geographic locale and business model.
Full details of the 2008 Medical Economics survey for healthcare professionals are available at http://medicaleconomics.modernmedicine.com.
About ModernMedicine.com
ModernMedicine.com is an innovative online clinical decision-support resource that provides healthcare professionals with instant answers to clinical and practice management questions from highly credible and trusted sources. Our mission is to become the leading online clinical decision-support, CME and practice management resource for healthcare professionals. ModernMedicine.com provides healthcare professionals with access to a robust, cross-specialty online medical library of updated content that is complemented by interactive tools and features. ModernMedicine.com features current and archived content from Advanstar’s award-winning journal portfolio including Medical Economics, Drug Topics, Contemporary OB-GYN and Urology Times. Covering 20 specialties from Allergy to Urology, Modern Medicine.com also provides reviews from more than 100 of the world’s top peer-reviewed medical journals, as well as comprehensive coverage from over 50 major industry conferences and scientific sessions. Alerts and institutional updates from NIH, FDA, CDC and other government agencies are reported in real time as part of the medical resources on our healthcare professional website.
See Also:
- 1200 Bottles of Vitamins “Going to the Dogs” and Charity
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- What Price Presidency?
[Via PRWeb: Medical General]
Is Back Strain Causing Your Urinary Tract Infection?
| Furl It |
Lower Back Pain Can Lead to Trouble
Edison, NJ (PRWEB) September 3, 2008 — Women, anatomically, are more prone than men to experience a urinary tract infection (UTI), yet their lifestyle habits, such as carrying heavy purses and wearing high heels, can actually increase this risk. Whether it is from fashion, exercise, or heavy lifting, an injured lower back (either the muscles or nerves or both) can increase the risk of a UTI.
“Back injuries can often disrupt or inhibit urine flow,” says Larrian Gillespie, a retired urogynecologist and author of the book, You Don’t Have to Live with Cystitis, The Groundbreaking Guide to the Prevention and Cure of One of Women’s Most Stubborn Ailments (Quill, An Imprint of HarperCollins Publishers). “As a result, UTI-causing bacteria become trapped in the bladder causing a urinary tract infection.”
UTIs are related to back problems by a few factors, explains Gillespie. The lower back has many fine nerves that can become strained from lifting something very heavy once, or something mildly heavy all of the time/daily, when exercising, from altered posture, etc. “The discs in the lower back can also become damaged, which can compress the nerves that signal the bladder to empty, causing disruption to urine flow,” says Gillespie. Improper urine flow, she adds, keeps the bacteria in the bladder from being flushed out, which can result in a UTI.
Over-exerting oneself while exercising can also cause back strain. “Ensure the use of proper workout techniques by participating in aerobic activities that give you a natural, fluid motion, such as walking,” Gillespie advises. “And use weight machines instead of free weights and ask gym personnel for guidance in showing you how to properly use the weight machines.” She adds that if a person currently suffers from back injuries, swimming is ideal because it creates the least pressure on this area.
Gillespie also says to beware of your high-fashion accessories, such as ultra high heels and large, heavy pocketbooks and totes. “Women who repeatedly wear high-heeled shoes that are too high for their hip and leg structure can cause their pelvis to tilt forward, which takes their hips and spine out of alignment,” she warns. By continuously wearing these high-heeled shoes or boots, they develop a “swayback,” also known as lordosis, which is a painful condition that creates pressure on the nerves in the lower back. This pressure Gillespie says, contributes to inefficient urination, which is a precursor for urinary tract infections (UTIs).
In addition, carrying a heavy backpack or purse can contribute to the development of “lordosis.” According to Time magazine’s special Style issue, in 2007, the average weight of a woman’s purse was 5.2 pounds. “If that’s the average weight of a purse, imagine the weight of briefcases, backpacks, tote bags, and the like!” she says.
“There is an over-the-counter medication that women can take preventatively if they are prone to lower back problems that result in recurring UTIs,” says Gillespie. “Cystex is a urinary medication that contains the natural antiseptic methenamine that helps stop bacteria from adhering to the walls of the urinary tract, thereby helping to prevent the infection from occurring in the first place.” Cystex® also contains a reliable analgesic to stop the painful symptoms of a urinary tract infection while waiting to see a doctor.
To learn more about Cystex®, as well as other important information about urinary tract infection prevention and care, visit http://www.cystex.com. The site also houses the Ladies Room blog, as well as a partnership with the “Bathroom Diaries,” which is a listing of reliable, clean public restrooms in various cities throughout the U.S.
See Also:
- DuPont Building Innovations Announces Price Increases
- Website Expanded to Raise Awareness About the Cruelty at Puppy Mills and to Help End the Suffering of Dogs
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- Economy: Recession Shakes Up Jewelry Industry & A New Approach Has Emerged
- DuPont Building Innovations Announces Price Increases
[Via PRWeb: Medical General]